Non-Coding RNAs in Colorectal Cancer: Their Functions and Mechanisms

Zimo Jia¹, Jiaqi An¹, Ziyuan Liu² and Fan Zhang¹,3*

¹ Department of Biochemistry and Molecular Biology, Hebei Medical University, Shijiazhuang, China, ² School of Medicine, Shihezi University, Shihezi, China, ³ The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Shijiazhuang, China

Colorectal cancer (CRC) is a common malignancy with high mortality. However, the molecular mechanisms underlying CRC remain unclear. Controversies over the exact functions of non-coding RNAs (ncRNAs) in the progression of CRC have been prevailing for multiple years. Recently, accumulating evidence has demonstrated the regulatory roles of ncRNAs in various human cancers, including CRC. The intracellular signaling pathways by which ncRNAs act on tumor cells have been explored, and in CRC, various studies have identified numerous dysregulated ncRNAs that serve as oncogenes or tumor suppressors in the process of tumorigenesis through diverse mechanisms. In this review, we have summarized the functions and mechanisms of ncRNAs (mainly lncRNAs, miRNAs, and circRNAs) in the tumorigenesis of CRC. We also discuss the potential applications of ncRNAs as diagnostic and prognostic tools, as well as therapeutic targets in CRC. This review details strategies that trigger the recognition of CRC-related ncRNAs, as well as the methodologies and challenges of studying these molecules, and the forthcoming clinical applications of these findings.

Keywords: ncRNAs, colorectal cancer, function, mechanism, tumorigenesis

INTRODUCTION

Colorectal cancer (CRC), with a high incidence and mortality rate, is the third most prevalent malignant tumor and the second leading cause of cancer-related death worldwide (1). Globally, there are two main distinct pathways of precursor lesions: the conventional adenomatous carcinoma pathway (also known as the chromosomal instability sequence) leading to 70%-90% of CRC, and the serrated neoplasia pathway leading to 10%-20% of CRC (2). These pathways represent a diverse multiplicity of genetic and epigenetic events in a fairly consistent sequence (3). The chromosomal instability phenotype typically develops after a genomic event triggered by an APC mutation, followed by RAS activation or function loss of TP53. In contrast, the serrated neoplasia pathway is associated with RAS and RAF mutations and epigenetic instability characterized by a CpG island methylation phenotype, leading to microsatellite stable and unstable cancers (2). Due to the lack of distinctively incipient symptoms and the limitations of early detection, most CRC patients are diagnosed at advanced stages. Metastatic disease accounts for the vast majority of cancer-associated deaths. And the liver is the most frequent site of distant metastasis from CRC, with over 50% of CRC deaths being attributed to metastasis (4). Despite advances in the diagnosis and treatment of CRC,
such as some practical chemotherapeutic drugs and immunotherapy, the genetic background and underlying molecular mechanisms mediating this disease are still unclear (5). Although the increased risk of toxicity and cost, new therapeutic agents have exactly improved survival in advanced disease settings. However, the long-term prognosis for metastatic disease remains poor due to late diagnosis and treatment failure (6). To improve CRC therapy, novel potent drugs require identification, and therapeutic strategies need to be appraised and developed.

The result of the human genome project shows that protein-coding genes represent less than 2% of the total human genome, whereas, more than 90% of the human genome is composed of non-coding RNAs (ncRNAs), which are actively transcribed from the human genome but cannot encode proteins (7, 8). ncRNA families are habitually divided into two broad categories. One is housekeeping ncRNA, including highly abundant ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs). The other is regulatory ncRNAs, including long ncRNAs (lncRNAs), microRNAs (miRNAs), circular RNAs (circRNAs), PIWI-interacting RNA, tRNA-derived small RNA (tRFs), small nucleolar RNA (snoRNAs), siRNAs, and so on (9). Among the most studied classes of ncRNAs are lncRNAs, miRNAs, and circRNAs.

As one of several types of ncRNAs, lncRNAs are larger transcripts with more than 200 nucleotides (nt) in length, and a considerable portion of lncRNAs species are transcribed by polymerase II. Similarly, most have 5′-end m7G caps and 3′-end poly(A) tails, and they are presumed to be transcribed and synthesized in the same way as mRNAs, but cannot translate into protein (10). There are two types of functional elements in lncRNAs, one is the interactor element that directly interacts physical with other molecules, and proteins, and the other is the structural element, which leads to the formation of secondary and/or tertiary 3D RNA structures and regulates their functional interactions (11). It is the ability to interact with RNA and proteins through rigorous base pairing or chemical interactions in secondary structures that enables lncRNAs to function in various ways. Many lncRNAs have been identified to play a role in gene regulation, for instance, by affecting transcription factor targeting or epigenetic modification. In addition, interactions with mRNAs might cause the alteration of their transcriptional speed and stability. As such, the interaction between lncRNAs and proteins may affect protein activity, stability, or localization (12, 13).

miRNAs are highly conserved, small, 21–22 nts in length, single-stranded ncRNAs, regulating a wide range of biological processes, including cell proliferation, differentiation, and apoptosis (14). The biogenesis of miRNAs is a multistep process (Figure 1). First, the miRNA gene is generally transcribed by RNA polymerase II and III as primary miRNA (pri-miRNA), which is dissected into 70 nts long precursor miRNA (pre-miRNA) by nuclear ribonuclease Drosha, and then exported to the cytoplasm by exportin-5 (15). Finally, the pre-miRNA is cleaved by Dicer into the double-stranded miRNA, of which the passenger strand is degraded. The mature miRNA strand is integrated into Argonaute (AGO) protein in the RNA-induced silencing complex (RISC) to mediate translational repression by targeting mRNAs. Moreover, in addition to interacting with mRNAs, miRNAs can also target IncRNAs and circRNAs, and competing endogenous RNAs (ceRNAs) manipulate other RNA transcripts by competing for shared miRNA (16, 17).

As a novel class of endogenous ncRNAs, circRNAs were initially considered as non-functional by-products of alternative splicing (18). Subsequent reports have elucidated that circRNAs can serve as miRNAs sponges, mediate alternative splicing, and regulate the expression of parental genes (19).

Most recently, since the widespread implementation of tiled microarray and high-throughput sequencing techniques across the entire genome and transcript, ncRNAs have gained extensive attention as a promising tool for curing cancer. Multiple studies have uncovered that ncRNAs are involved in multiple biological processes, for example, cell proliferation, apoptosis, differentiation, and transcription (8, 20). Subsequent investigations indicate that ncRNAs are indispensable for the modulation of a variety of cancers, for example, hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer, and so on (21). Moreover, studies focusing on the functions of ncRNAs in CRC have increased in recent years. Numerous ncRNAs have been demonstrated to be involved in CRC development and progression (Figure 2). For instance, an isolated report showed that IncRNA KCNQ1OT1 was significantly overexpressed in CRC tissue. By combining with miR-216b-5p, KCNQ1OT1 could elevate the expression of ZNF146, thereby leading to an acceleration of CRC proliferation, migration, and invasion (22). Additionally, evidence is accumulating that ncRNAs can provide the possibility for exploring molecular targeted therapy and novel drug development for healing CRC patients. And these ncRNAs are relevant to the diagnosis and prognosis of CRC; therefore, the expression of ncRNAs is regarded as a regulatory factor crucial for the progression of CRC. Because the investigation of ncRNAs and cancer hallmarks, as well as tumorigenesis in CRC, has grown impressively over the last decade, making it impossible to cover each published paper. In this review, we focus on the role of prominent ncRNAs, such as IncRNAs and miRNAs, and recently emerging circRNAs in CRC development, tumorigenesis, and metastasis, as well as their clinical significance, hoping to offer a novel approach to the treatment of CRC. Other ncRNAs such as piRNAs, snoRNAs, and siRNAs will be explored in a subsequent paper.

**NCRNAS AND CRC**

**IncRNAs and CRC**

Deregulation of IncRNA transcripts has been associated with CRC investigation to date and influences primary cancer hallmarks such as proliferation, apoptosis, metastasis, invasion, and angiogenesis (23). Additionally, IncRNAs have been...
associated with other biological processes such as metabolic disorders and drug resistance (Table 1).

The ability of carefully selected lncRNAs to target multiple pathways that are altered in CRC makes these molecules interesting candidates for therapeutics or targets of therapeutics. HOTAIR is a well-studied lncRNA that has been widely reported as an oncogenic molecule in CRC. Previous studies had disclosed that HOTAIR knockdown inhibited cell proliferation, invasion and migration, while promoting apoptosis and enhancing cell radiosensitivity in CRC (44). A recent study showed that knockdown of HOTAIR decreased cell viability, promoted apoptosis, and inhibited cellular autophagy in CRC through upregulation of miR-93 and downregulation of autophagy-associated 12 (ATG12) (45). Furthermore, deletion of HOTAIR enhanced radiosensitivity by regulating the miR-93/ATG12 axis in CRC cells and CRC xenograft tumor models. lncRNA HOTTIP expression levels of CRC patients are identified to be elevated and intimately relative to the clinical stage and distant metastasis. Knockdown HOTTIP markedly attenuates the proliferative and migratory capability of CRC cells (46). Interestingly, another study has found that SGK1 is dramatically downregulated compared with control when HOTTIP is knocked down in HCT116 and SW620 cells. Furthermore, the decreased SKG1 can promote the expression of GSK3β and inhibit the expression of FOXO3a, which is consistent with the result of knockdown HOTTIP (47). It is worth noting that whether knockdown HOTTIP is associated with SKG1 downregulation in CRC needs further experimental verification. To prioritize all RAMS in metastatic CRC (mCRC), Silva-Fisher et al. studied whether the expression of lncRNAs is related to patient outcome (48). Notably, they found that lncRNA RAMS11 is a top upregulated lncRNA and can promote CRC growth and metastasis. And its abnormal expression also predicted unfavorable outcomes in CRC patients, suggesting the great role of RAMS11 expression as a biomarker for identifying high-risk patients (48). Another study showed that downregulation of RAMS11 significantly represses proliferation, autophagy, metastasis, and invasion of HCT-116 and SW480 cells in vitro. More importantly, the crucial pathway investigation suggests that Dsi-RAMS11 potentially promotes apoptosis and autophagy via phosphorylation of AMPK and suppression of AKT and mTOR signaling pathways (49). As a
consequence, through autophagy, apoptosis and AKT/AMPK/mTOR signaling pathways, RAMS11 downregulation is negatively associated with proliferation and metastasis of CRC cells. However, an important limitation of this study is the absence of in vivo demonstration, which may further confirm the conclusions. These results above support the view that cell death by lncRNA RAMS11 may occur via more than one regulatory mechanism and fundamental differences may exist between the AKT and mTOR pathways. Several additional lncRNAs have been implicated in CRC progression. Pharmacological screens reveal that RAMS11 enhances CRC resistance to topoisomerase inhibitors and provides mechanistic insight into the RAMS11-dependent TOP2 regulation that promotes mCRC promotion.

**miRNAs and CRC**

At the beginning of the 21st century, Michael et al. found the expression of miR-143 and miR-145 were downregulated in CRC, firstly associating miRNA with CRC development (50). To date, among all types of ncRNAs, miRNAs are the best understood, which have been well studied in the occurrence and progression of CRC (5, 51). Accordingly, these molecular changes stimulate proliferation, apoptosis, metastasis, angiogenesis, and drug resistance of CRC. Particularly, the distribution of miRNAs in tumors has characteristics related to CRC diagnosis, prognosis, and response to treatment. Hence, we have summarized the functions and mechanisms of key miRNAs (Table 2).

**miR-124**, a repressive miRNA downregulated in CRC tissues, mainly through upregulating and downregulating the expression of related target genes and thus modulating molecular signaling pathways, affecting the development and treatment of CRC. On one hand, aberrantly methylated miR-124 is capable of elevating the expression of DNMT3B to promote CRC proliferation, invasion and migration (69). 5-Aza-CdR can reverse the expression level of miR-124 in Hct-116 cells by inhibiting methylation, thus reducing the expression of DNMT3B and decreasing cell proliferation, migration and invasion. On the other hand, miR-124 can target a specific region in PD-L1 3’ untranslated region (UTR) to reduce PD-L1 mRNA, protein, and cell surface expression, therefore inhibiting Tregs induction and CRC immunosuppression. As a result, the viability and proliferation of CRC cells are significantly diminished (70).

Besides, miR-124 overexpression inhibits CRC proliferation and arrests the cell cycle at the G1 phase by downregulating c-Myc and induces apoptosis in CRC cells via upregulation of both intrinsic and extrinsic pathways. The underlying mechanism is that miR-124 downregulates Bcl-2 expression and increases the level of Bax pro-apoptotic gene, which subsequently may lead to the induction of apoptosis. miR-200 family, which modulates the expression of proteins involved in tumor metastasis and angiogenesis, is another causative collection of miRNAs downregulated in CRC. miR200 family is categorized into two groups: miR200a/b/429 and miR200c/141, which are located on chromosomes 1 and 12, respectively (71). Despite the different chromosomal locations and differences in expression patterns...
between the two parts, there is a significant overlap in their targets and biological functions, mainly involving components that play a role in epithelial-mesenchymal transition (EMT). And the EMT program in cancer cells is associated with an increase in cancer metastasis. Additionally, miR-200 directly inhibits the transcriptional inhibitor zinc finger E-box-binding homebox 1, a known transcriptional suppressor of the cytoskeletal rearrangement protein E-cadherin, thus inducing homeobox 1, a known transcriptional suppressor of the E-cadherin and N-cadherin that engaged in EMT (72).

EGFR (also known as Her1) is a human epidermal growth factor receptor belonging to a family of HER-related proteins that can be selectively activated by some different ligands (73). Once the ligand binds to EGFR, the receptor forms a dimer that initiates autophosphorylation of the receptor via tyrosine kinase activity within the receptor. Autophosphorylation triggers a series of signaling events, mainly through the RAS/RAF/MEK/MAPK and PI3K/AKT pathways (74). These pathways are responsible for cancer cell proliferation, activation of invasion and metastasis, blockade of apoptosis, and promotion of angiogenesis. Dysregulation of the EGFR pathway has been validated as a relevant procedure in CRC, and it has been identified as a target of several miRNAs. RASA1 is a member of RAS GTPase activating proteins (RAS-GAP) family (75). While the oncoprotein RAS can be inactivated by binding to the RAS-GAP members. miR-21 directly modulates RASA1 as a target of several miRNAs. RASA1 is a member of RAS/RAF/MEK/MAPK and PI3K/AKT pathways (74). These pathways are responsible for cancer cell proliferation, activation of invasion and metastasis, blockade of apoptosis, and promotion of angiogenesis. Dysregulation of the EGFR pathway has been validated as a relevant procedure in CRC, and it has been identified as a target of several miRNAs. RASA1 is a member of RAS GTPase activating proteins (RAS-GAP) family (75). While the oncoprotein RAS can be inactivated by binding to the RAS-GAP members. miR-21 directly modulates RASA1 as a target of several miRNAs. RASA1 is a member of RAS-GTPase activating proteins (RAS-GAP) family (75).

### TABLE 1 | Selected examples of regulatory IncRNAs.

| IncRNAs | Expression | Potential biomarker | Therapeutic value | Function | Target/ signaling pathway | Ref |
|---------|------------|---------------------|-------------------|----------|------------------------|-----|
| LINRIS  | ↓          | Prognosis           | NA                | Promote autophagy and apoptosis while inhibiting proliferation | IGF2BP2/Myc | (24) |
| TCONS_00012883 | ↑          | Prognosis, tumor size and TNM stage | NA | Promote proliferation and metastasis | DDR3/YY1/MMP | (25) |
| BLACAT1 | ↑          | Prognosis, TNM stage and distant metastasis | OX-A resistance and therapeutic target | Promote proliferation, migration, and invasion while inhibiting apoptosis | miR-519d-3p/CREB1/p53, GRWD1/ RPL11/MDM2 | (26) |
| PHL     | ↑          | Prognosis           | 5-FU resistance and therapeutic target | Promote proliferation, and colorectal xenograft tumors | Integrin-mediated focal adhesion | (27) |
| ITGB8-AS1 | ↑          | Diagnosis           | Therapeutic target | Promote cell proliferation and migration | | (28) |
| AGO10789.1 | ↑          | Prognosis and lymphatic metastasis | NA | Promote proliferation, migration, invasion, and EMT | mR-432-3p/ZEB1, Wnt/β-Catenin | (29) |
| DNAJC3-AS1 | ↑          | Prognosis and TNM stage | NA | Promote proliferation, migration and invasion and, and lipid accumulation | EGF/P3K/ AKT/NF-kB/SREBP1 | (30) |
| HOTAIR  | ↑          | Prognosis and diagnosis | 5-FU resistance and therapeutic target | Promote viability, migration, invasion and EMT | SNAIL/HNF4α, miR-218, NF-kB/TS | (31) |
| GAS5    | ↓          | Diagnosis           | NA | Inhibit migration and invasion while promoting apoptosis, autophagy, and AVO activities | mR-222-3p/GAS5/PTEN | (32) |
| KCNQ1OT1 | ↑          | Diagnosis           | Cisplatin resistance and therapeutic target | Promote cell motility and proliferation while inhibiting apoptosis | mR-216b-5p/ ZNF14,mR-497/Bcl-2 | (33) |
| FLANC   | ↑          | Prognosis           | Therapeutic target | Promote proliferation, migration, and angiogenesis while inhibiting apoptosis | STAT3/ VEGFA | (34) |
| NEAT1   | ↑          | Prognosis           | NA | Promote proliferation, migration, metastasis and invasion | DDX5/Wnt/β-catenin | (35) |
| TPT1-AS1 | ↑          | Prognosis TNM stage, tumor size, lymphatic metastasis, and distant metastasis | NA | Promote invasion, metastasis and angiogenesis | NF90/VEGFA | (36) |
| H19     | ↑          | Prognosis           | 5-FU resistance and therapeutic target | Promote autophagy | SIRT1 | (37) |
| MCF2L-AS1 | ↑          | Prognosis           | NA | Promote proliferation, invasion, and glycolysis | mR-874-3p/FOXM1 | (38) |
| RAD51-AS1 | ↓          | Prognosis           | NA | Inhibit proliferation, migration, and glycolysis | mR-29b/c-3p/NDRG2 | (39) |
| ZNF667-AS1 | ↓          | Prognosis           | NA | Inhibit proliferation, migration, and invasion | ANK2/JAK2 | (40) |

1, up-regulate; ↓, down-regulate; EMT, epithelial-mesenchymal transition; TNM, tumor node metastasis; 5-FU, 5-fluorouracil; OXA, oxaliplatin; NA, not available.
reciprocal manner, Wnt ligands lead to EGFR transcription through metalloproteinase-dependent binding of the cell surface EGFR ligand epitope domain to its GPCR Frizzled receptor (77). For example, miR-139-5p is a novel regulator of crosstalk between the EGFR and Wnt signaling pathways in CRC. miR-139-5p, a KRAS-responsive miRNA, is significantly downregulated in KRAS-mutated CRC tissues and cells, and its transcription is repressed by Wnt/β-catenin signaling in mutant CRC cells (78). miR-139-5p inhibits CRC cell proliferation and metastasis by targeting multiple regulators of the RAS and Wnt signaling pathways and EMT.

Nowadays, numerous lines of reports show that miRNAs serve as oncogenes or tumor suppressors in CRC evolution (79). The critical roles of miRNAs in the pathogenesis of CRC confirm their suitability for therapeutic development.

### circRNAs and CRC

Currently, there are numerous lines of studies focusing on the mechanisms of lncRNAs and miRNAs. Compared to them, the investigation of circRNAs in the progression of human disease is still in its infancy (80, 81). Although the role of circRNAs is less well characterized in other human disorders, most studies have focused on the role of circRNAs in cancers.

**ciRS-7**, as a type of endogenous circRNA with a closed circular structure, was first identified by Hansen in 2011 (82). ciRS-7 plays a vital role in the transcription of RNA, the expression of downstream genes, and the synthesis of protein. Furthermore, ciRS-7 functions as an oncogene and stimulates tumor progression by competitively repressing miR-7 in various types of cancers, including CRC (82). Another study found that miR-7-mediated inhibition of the EGFR/RAF1/MAPK pathway could be alleviated by overexpression of ciRS-7 in CRC (83). Despite the mutational status of KRAS or BRAF oncogenes, miR-7 could effectively inhibit this pathway in CRC cell lines. This is due to the fact that miR-7 was able to suppress the expression of not only EGFR but also another key MAPK member, RAF1 (84). Interestingly, ciRS-7 resulted in sustained activation of the EGFR/RAF1/MAPK pathway in CRC cells regardless of the mutational status of KRAS or BRAF oncogenes, miR-7 precursors. Thus, dual targeting of ciRS-7 and miR-7 could provide CRC patients with a novel therapeutic strategy to inhibit this oncogenic pathway. In addition, high ciRS-7 expression was linked to a number of clinic-pathological factors, including advanced T-stage, lymphatic and distant metastases, and consequently, patients with higher expression of ciRS-7 had a poor prognosis (83).

Most recently, an increasing number of circRNAs have been observed to be aberrantly expressed in CRC (85). More specifically, their functions in tumorigenesis and metastasis have been reported, where individual circRNAs are considered to be carcinogens or tumor suppressors. For example, Chen et al. discovered that treating RKO and HCT116 cells with cobalt chloride (Cocl2, a hypoxia mimic) or TGF-β increased circERBIN expression, implying that ERBIN may be involved

### Table 2

**Selected examples of regulatory miRNAs.**

| miRNAs     | Expression | Potential biomarker          | Therapeutic value                                      | Function                          | Target/signaling pathway | Ref  |
|------------|------------|------------------------------|--------------------------------------------------------|-----------------------------------|--------------------------|------|
| miR-30b-5p | ↓          | Liver metastasis             | NA                                                     | Inhibit invasion and migration, EMT, adhesion, and motility | Rap1b                    | (52) |
| miR-123b   | ↓          | NA                           | OXA and 5-FU resistance                                  | Inhibit migration, invasion, stemness, and drug resistance | DOT1L/K3K7me2, LUCAT1/EZH2 | (53), (54) |
| miR-450a-5p| ↑          | Prognosis                    | NA                                                     | Promote stemness and angiogenesis | SOX2                    | (55) |
| miR-25-3p  | ↓          | Diagnosis                    | NA                                                     | Promote metastasis and angiogenesis | KLF2, KLF4               | (56) |
| miR-133b   | ↓          | Lymphatic metastasis         | OXA resistance and therapeutic target                   | Inhibit autophagy while promoting apoptosis | SIRT1, TGF-β/Smad4       | (57) |
| miR-106b-3p| ↓          | Prognosis                    | NA                                                     | Promoted migration, invasion, and EMT | DCL-1                    | (58) |
| miR-302a   | ↓          | Lymphatic metastasis         | Fluorouracil, doxorubicin, and cisplatin resistance     | Inhibit migration and chemotherapy resistance | NFIβ/TGαB                | (59) |
| miR-138-5p | ↓          | Prognosis and liver metastasis| Ozetuximab resistance and therapeutic target            | Inhibit proliferation and metastasis | c-met, Snail/β-catenin   | (60), (61) |
| miR-146a   | ↓          | Prognosis                    | 5-FU resistance                                         | Inhibit proliferation, migration, invasion, EMT, stemness, and M2-like TAM polarization | NOTCH2/GATA3/IL-4 | (62), (63), (64) |
| miR-195-5p | ↑          | NA                           | NA                                                     | Promote proliferation, cell cycle, migration and invasion while inhibiting apoptosis | INGS                     | (65) |
| miR-196b-5p| ↑          | Lymphatic metastasis         | NA                                                     | Inhibit proliferation and metastasis | PLAGL2/MYH9              | (66) |
| miR-214-5p | ↓          | Prognosis and tumor size     | NA                                                     | Promote metastasis and invasion | SP1-Mediated NF-κB       | (67) |
| miR-1224-5p| ↓          | Prognosis                    | NA                                                     | Inhibit metastasis, invasion and EMT | INGS                     | (68) |
| miR-875-3p | ↓          | Prognosis and distant metastasis| NA                                                     | Inhibit proliferation and migration | PLK1                     |      |

↑, up-regulate; ↓, down-regulate; EMT, epithelial-mesenchymal transition; OXA, oxaliplatin; 5-FU, 5-fluorouracil; NA, not available.
in cancer progression (86). They also found that ERBIN was highly expressed in CRC cells, and the overexpression of ERBIN facilitated metastasis of CRC cells in vitro and in vivo. ERBIN exerts its oncogenic effects through regulating multiple cellular pathways, including those involved in CRC angiogenesis, proliferation, invasion, and migration. Mechanistically, ERBIN is known to directly sponge miR-125a-5p and miR-138-5p, accelerate the cap-independent protein translation of HIF-1α, and target eukaryotic translation initiation factor 4E binding protein (86).

Moreover, some studies have unveiled the great potential of circRNAs as promising prognostic markers or biomarkers in patients with CRC (87). Unlike linear RNA molecules, circRNAs possess a covalent closed-loop structure with high stability, preventing degradation induced by the exonuclease RNaseR. Furthermore, circRNAs with cell-specific or stage-specific expression patterns can be found in tissue samples, saliva, or plasma (18). These features could partially explain the possible application of circRNAs as prospective biomarkers. circ002144 expression is dramatically increased in CRC and is positively correlated with cell proliferation, migration, and invasion. The abnormal expression of circ002144 is also closely relevant to tumor progression, which implies that circ002144 may become a promising biomarker in the prognostic evaluation of CRC (88). It is worth noting that a high level of serum circ0004771 can be partially explained by the occurrence of liver tumors. Here, we have briefly epitomized the action of important circRNAs in the progression of CRC (Table 3). These studies have illustrated the large diversity of strategies by which ncRNAs could modulate oncogenes or tumor suppressors to influence CRC progression.

THE FUNCTIONS AND MECHANISMS OF NCRNAS IN CRC

cRNAs Modulate CRC Proliferation and Apoptosis

Arguably, the most fundamental feature of malignant cells involves their ability to sustain chronic proliferation (111). The proliferation process of normal cells is induced by cell cycle alternation and receptor tyrosine kinases (PTKs) activation. Interestingly, the procedure can be restricted by themselves, whereas both cell cycle checkpoints ignorance and constituent activation of RTKs failure will lead to tumorigenesis (112). At the same time, proliferation must be tolerated by tumor cells, or tumor growth will be hindered and the cells will enter senescence. Apoptosis, as a programmed cell death that occurs during the advancement or aging process of normal cells, is a kind of homeostatic mechanism to maintain the stabilization of the cell population. There are several main apoptotic pathways: the endogenous or mitochondrial pathway and the exogenous or death receptor pathway, as well as the perforin/enzyme pathway. Several of the aforementioned pathways converge at the same execution pathways or terminals, which are initiated by caspase-3 cleavage (113). Apoptosis is activated in case of extrinsic or intrinsic stressors, exerting an antitumorigenic role. In conclusion, apoptosis is a promising target for the treatment of tumors.

Recent studies indicated that several typical ncRNAs play indispensable roles in CRC proliferation and apoptosis (Figures 3A, B) (94, 97). It has been identified that IncRNA SLCO4A1-AS1 is highly expressed in CRC cells, and there is a strong link between higher SLCO4A1-AS1 abundance and proliferation and apoptosis, as observed in CRC. By affecting activation of Wnt/β-catenin signaling, SLCO4A1-AS1 can mediate many cellular processes, such as cell proliferation, migration, differentiation, and apoptosis (114, 115). Consequently, elevated SLCO4A1-AS1 induces the hyper-activation of the Wnt/β-catenin signaling, thus leading to sustained proliferative ability and attenuated apoptotic behavior of CRC cells (116). Further analysis shows that SLCO4A1-AS1 knockdown severely reduced protein levels of β-catenin but not mRNA levels by the mechanism that SLCO4A1-AS1 represses phosphorylation of β-catenin, which in turn inhibits ubiquitination-mediated degradation. The more significant findings to emerge from this study is that SLCO4A1-AS1 modulated β-catenin stability by weakening the link between β-catenin and GSK3β, thereby influencing tumor progression (116). Another way that SLCO4A1-AS1 may modulate tumorigenesis is by sponging miR-508-3p, thus upregulating PARD3 and promoting CRC cell proliferation (117). Ectopic expression of circSPARC is detected in both CRC patients’ tissues and plasma. It has been unveiled that SPARC could manipulate STAT3 expression to stimulate CRC proliferation by elevating the level of c-Myc. The process mainly involves two different pathways. On the one hand, SPARC functions as a miR-485-3p decoy to enhance JAK2 activation. On the other hand, it can interact with FUS to stimulate the nuclear translocation of activated p-STAT3 (118). Another study uncovered that miR-485-3p is detected to be extensively downregulated in CRC tissues. The dysregulation of miR-485-3p is positively correlated with P21 expression and negatively correlated with TPX2 expression (119). Since the underlying mechanism has not been discussed yet, more work is needed to definitively identify the specific regulation of miR-485-3p.

It is widely believed that genetic mutations promote the uncontrolled growth and proliferation of tumor cells. However, the situation may be more complex than that. A recent study showed that there are more than 100 mutated tumor suppressor genes that do not act directly on cancer cells (120). The mechanism that drives cancer cell growth is to prevent the immune system from recognizing and destroying tumor tissue, which is the real cause of the uncontrolled spread of cancer cells. Interestingly, these mutated genes are instructing the cancer cells how to evade the immune system, rather than simply saying “grow, grow”. This may broaden our understanding of the
changing traditional concept of proliferation and provide new insights for future research.

**ncRNAs Regulate CRC Metastasis**

The metastatic establishment of CRC at distant organs is largely incurable and primarily contributes to the deaths of CRC patients. EMT represents the first step of metastasis and is intimately linked with the acquisition of a migratory phenotype in CRC cells (121). EMT is characterized by the loss of epithelial polarity and breakdown of tissue architecture, including the cell adhesion, the acquisition of N-cadherin and E-cadherin expression, thereby leading to the destabilized adherens junctions and increased cell mobility (122). Invasion-metastasis involves EMT and its reverse counterpart, the mesenchymal-epithelial transition, both of which are normally activated during embryonic development and tissue homeostasis, contributing to proper morphogenesis of tissues and organs (123).

Molecular underpinnings for dissemination of mCRC have been uncovered by accumulating novel paradigms in the study of mCRC (124). For instance, recent studies have illustrated the novel function of lncRNA MALAT1 in accelerating CRC metastasis through two intercellular signal transductions (125). One is MALAT1 restricting the influence of miR-15 on the

**TABLE 3 | Selected examples of regulatory circRNAs.**

| circRNAs | Expression | Potential biomarker | Therapeutic value | Function | Target/signaling pathway | Ref |
|----------|------------|---------------------|-------------------|----------|--------------------------|-----|
| 0001946  | ↑ Prognosis | NA                  | Inhibit growth, migration, and invasion while promoting EMT | miR-135a-5p/EML | (90)                      |
| cRS-122  | ↑ NA       | OXA resistant and therapeutic target | Promote glycolysis and ATP production | miR-122/PKM2 | (91)                      |
| 100290   | ↑ Prognosis | NA                  | Promote proliferation, migration and invasion while inhibit apoptosis | miR-516b/FZD4/Wnt-β-catenin | YY1/CTNNB1 | (92)                      |
| AGFG1    | ↑ Liver metastasis | NA | Promote proliferation, migration, and invasion while inhibit apoptosis | miR-516b/FZD4/Wnt-β-catenin | YY1/CTNNB1 | (93)                      |
| 103809   | ↓ Lymphatic metastasis and clinical stage | NA | Promote proliferation and migration | miR-532-3p/FOXO4 | (94)                      |
| 102209   | ↑ Histological grade and liver metastasis | NA | Promote proliferation, migration, invasion and EMT while inhibiting cell cycle arrest and apoptosis | miR-761/RIN1 | (95)                      |
| 102958   | ↑ Prognosis and clinical stage, lymphatic metastasis | NA | Promote proliferation, migration and invasion | miR-585/CDGβ3 | (96)                      |
| 001680   | ↑ Prognosis, lymphatic and visceral metastases, and therapeutic target | NA | Inhibit irinotecan resistance and therapeutic target | miR-340 /BMI1 | (97)                      |
| 0007845  | ↑ Lymphatic and liver metastasis, and advanced clinical stage | NA | Promote proliferation and metastasis | miR-4736/CSE1L | (98)                      |
| 002144   | ↑ Prognosis, tumor size, lymphatic and distant metastasis, and TNM stage | NA | Promote viability, proliferation, migration, and invasion while inhibiting apoptosis | miR-615-5p/LARP1/mTOR | (99)                      |
| 0000932  | ↑ Diagnosis, pathological stage, lymphatic and distant metastasis | NA | Promote proliferation and motility while inhibiting apoptosis | miR-193a-5p/PIK3R3/AKT | (100)                     |
| ITGA7    | ↓ Lymphatic metastasis, tumor size, and TNM stage | NA | Inhibit proliferation and metastasis | RAS | (101)                      |
| CCDC66   | ↑ Hypoxia | NA | Promote viability, migration, and invasion while inhibiting apoptosis | miR-3140 /autophagy | (102)                     |
| circ-133 | ↑ Hypoxia and TNM stage | NA | Promote proliferation and cell cycle | TNKS, Wnt-β-catenin | (103)                     |
| circ5615 | ↑ Prognosis and TNM stage | NA | Promote proliferation and cell cycle | N1-2 neutrophils differentiation | (104)                     |
| FBXW7    | ↓ Tumor size | NA | Inhibit proliferation, migration and invasion | NEK2, mTOR, and PTEN | (105)                     |
| PACRGL   | ↑ Prognosis | NA | Promote proliferation, migration, invasion, and N1-N2 neutrophils differentiation | miR-142-3p, miR-506-3p/TGF-β1 | (106)                     |
| FNDC3B   | ↓ Prognosis | NA | Inhibit proliferation, invasion, and angiogenesis | miR-97-5p/TIMP3 | (107)                     |
| 001971   | ↑ Tumor size, TNM stage, and lymphatic metastasis | NA | Promote proliferation, invasion, and angiogenesis | miR-29c-3p/VEGFA | (108)                     |
| ZNF609   | ↓ Diagnosis and tumor size | NA | Promote apoptosis | p53 | (109)                      |
| 0026344  | ↓ Prognosis, diagnosis, and lymphatic metastasis | NA | Inhibit proliferation and invasion while promoting apoptosis | miR-21, miR-31 | (110)                     |
| RAE1     | ↑ Prognosis, metastasis, and tumor size | NA | Promote migration and invasion | miR-338-3p/TYR3 | (111)                     |

↑, up-regulate; ↓, down-regulate; EMT, epithelial-mesenchymal transition; TNM, tumor node metastasis; OXA, oxaliplatin; NA, not available.
transcriptional levels of LRP6 by sponging miR-15 family members, which expedites β-catenin signaling, while the other is MALAT1 binding SFPQ and interacting with the IRES domain in the 5′-UTR of the corresponding RUNX2 mRNA. As a result of both functional mechanisms, the downstream target gene RUNX2 is elevated at the transcriptional level, which is eventually linked to CRC metastasis (125).

The results of another study have revealed that circAGFG1 is upregulated with a significant increase in CRC metastasis (93). circAGFG1 directly binds to miR-4262 and miR-185-5p to enhance YY1 expression and CTNNB1 transcription, contributing to an acceleration of CRC metastasis (93). Consistently, the expression of lncRNA H19 is higher in mesenchymal subtypes of CRC cells than in epithelial subtypes. In CRC, H19 is found to be specifically overexpressed clones capable of seeding metastases, while short hairpin RNA (shRNA)-mediated knockdown of H19 in metastasis-capable clones abrogates the development of distant metastases (126). Based on this study, H19 acts as a ceRNA against miR-200b and miR-200c, resulting in derepression of ZEB1 and GIT2 in primary tumors and distant metastases. Nonetheless, GIT2 is shown to facilitate colonization at metastatic sites (127). An important strength of this study is relying on endogenous AGO pulldown, which provides biochemical support rather than nucleic acid sequence analysis or indirect measures of ceRNA activity, as well as targeted mutagenesis to verify the feature of H19 as ceRNA, despite the controversy regarding ceRNAs in general. Furthermore, miRNAs also exert an important role during CRC metastasis. Compared to normal tissues, the expression of miR-302a is substantially decreased in CRC tissues, especially in patient-derived xenografts and CTX-resistant cells. miR-302a overexpression inhibits metastasis in CRC cells and restores CTX responsiveness (59). miR-302a has also been observed to repress metastasis-promoting effect of NFIB that physiologically stimulates ITGA6 transcription. By decreasing CD44-induced cancer stem cell-like properties, EGFR-mediated MAPK, and AKT activation, miR-302a restores CTX responsiveness. Many ncRNAs have been demonstrated to be involved in EMT and metastasis of CRC (Figures 3C, D). Emerging evidence has depicted the specific functions and mechanisms of ncRNAs in CRC cells during their metastatic journey, which may be exploited to possibly halt metastatic growth and even prevent successful dissemination. Additionally, it would be interesting to see how these ncRNAs function during other steps in the

**FIGURE 3** | Diverse functions of non-coding RNAs (ncRNAs) in colorectal cancer. (A) A few ncRNAs regulate cell proliferation by promoting (e.g., lncBLACT1) or inhibiting cell proliferation progression (e.g., circITGA7). (B) Many ncRNAs modulate cell apoptosis via triggering (e.g., lncGAS5) or curbing (e.g., miR-196b-5p) cell apoptosis. (C) Several ncRNAs control the epithelial-mesenchymal transition (EMT) process through inducing (e.g., circ102209) or repressing (e.g., miR-30b-5p) EMT; E-cad, E-cadherin; N-cad, N-cadherin. (D) Certain ncRNAs manipulate tumor angiogenesis and metastasis procedure, some appear to facilitate tumor angiogenesis (e.g., circFLANC), while others restrain (e.g., circFNDC3B) the process; some promote metastasis (e.g., IncTPT1-AS1), while others inhibit (e.g., miR-1460) the process.
invasion-metastasis cascade. Future work will be designed to substantiate the mechanisms of these ncRNAs in contributing to EMT and metastasis and to find potential novel therapeutic approaches for the diagnosis and treatment of CRC.

**ncRNAs Manipulate CRC Angiogenesis**

Despite their physiological and morphological homogeneity, tumors display a wide range of morphological and phenotypic differences, including the expression of receptors on the surface of cells and their angiogetic capabilities (128). Angiogenesis is identified as an important hallmark of malignant tumors because quantities of blood vessels are needed to feed cancer cells (129). A number of ncRNAs have recently been demonstrated to be auxiliary diagnostic biomarkers for a range of cancers, and their expression varies among them. Likewise, the most recent research indicated that ncRNAs were heterogeneous in their regulation of tumor angiogenesis.

There are some frequently dysregulated ncRNAs involved in angiogenesis (Figure 3D). In clinical samples, miR-450a-5p is negatively correlated with SOX2 (55). An isolated study has discovered that miR-450a-5p induces angiogenesis via directly targeting the 3'-UTR regions of SOX2 in CRC (130). In addition, many miRNAs are packaged within tumor cell-derived exosomes, emerging as vital contributors to the complicated modulation and balance of pro-and anti-angiogenic molecules. Exosomal miR-25-3p-derived from CRC cells has been shown to be associated with angiogenesis (56). Exosomal miR-25-3p disrupts endothelial barrier integrity, increases vascular permeability, and simultaneously triggers angiogenesis. circ001971 expression is dramatically elevated in CRC tissues. Knockdown of circ001971 in CRC cells significantly interrupts HUVEC tube formation, consequently reducing the angiogenesis and tumor growth of SW620 cell-derived cancer in vitro (107).

VEGFA, a member of the growth factor family, has a strong capacity to activate the angiogenic milieu by increasing microvascular density and vascular permeability, which promotes tumor angiogenesis and metastasis and leads to tumors resistant to antiangiogenic therapy. The Krüppel-like factor (KLF) factor family is composed of zinc finger-containing transcription factors that regulate a variety of biological processes (131). miR-25-3p is recently been demonstrated to induce vascular permeability and angiogenesis in vascular endothelial cells by downregulating KLF2 and KLF4. Additionally, both KLF2 and KLF4 are downregulated in CRC (56). Specifically, KLF2 negatively regulates angiogenesis by inhibiting VEGFR221, whereas KLF4 maintains the integrity of endothelial barrier function by promoting tight junction-related proteins including ZO-1 and occludin5 (132). Furthermore, cir001971 acts as a ceRNA to relieve miR-29c-3p-induced VEGFA inhibition, which contributes to the aggravation of angiogenesis in CRC (107). An additional study indicated that LncRNA FLANC was involved in CRC angiogenesis via the STAT3/VEGFA pathway (36). Western-blot data confirmed that the overexpression of FLANC leads to a higher level of the phosphorylated STAT3, which acts as the active form triggering VEGFA (36). In conclusion, these findings lead to the determination that different ncRNAs exert multifaceted and even contradictory roles in regulating CRC angiogenesis through several distinct mechanisms, thereafter proving the heterogeneity of ncRNAs. Hence, we speculate that future research will focus on angiogenesis inhibitors and, how ncRNAs serve their roles in effective targeted therapies to repress angiogenesis will be studies focus.

**ncRNAs Regulate CRC Autophagy**

Autophagy is a cellular catabolic and evolutionarily conserved process, which removes redundant or dysfunctional components by dissociating the defective or malfunctioning organelles inside the cells (133, 134). Autophagy has a complex and context-dependent role in carcinogenesis. In addition to removing damaged organelles and aggregated proteins, autophagy serves as a surveillance mechanism to protect normal cells from the transformation into cancerous cells by reducing DNA damage, reactive oxygen species, and damaged mitochondria (135). Multiple lines of evidence have established that ncRNAs, as important regulatory molecules in CRC, are also involved in the autophagy of tumor cells (136). Once cancer occurs, autophagy is upregulated to ensure the survival of tumor cells in crisis circumstances such as hypoxia and growth factor deprivation. Inhibition or promotion of ncRNAs could decrease autophagy, allowing therapeutic strategies and treatment agents more effective (137). Through their ability to influence autophagy in CRC cells, miRNAs play a crucial role in the occurrence and development of CRC. The precise processes through which miRNAs influence autophagy and regulate cancer occurrence and progression have not been established. Inhibition of protective autophagy by miR-27b-3p may lead to increased sensitivity of CRC cells to chemotherapy, as ectopic expression of miR-27b-3p is downregulated in oxaliplatin-resistant CRC cells (HCT116-OxRS and W480-OxR) versus the corresponding parental cells. Impairing autophagy in CRC cells by reducing ATG10 expression can make them more susceptible to chemotherapeutic agents in vitro and in vivo, which is consistent with the report that miR-27b-3p levels positively correlate with disease-free survival time in CRC patients (138). Besides, LncRNAs also affect autophagy by modulating the expression of ATG genes, which are key regulators in the autophagy process (139). HOTAIR-mediated autophagy was reported to be a crucial event in the development and progression of CRC. As a molecular sponge of miR-93, LncRNA HOTAIR could modulate the expression of ATG12 to induce CRC autophagy (45). Through downregulation of miR-34a, LncRNA NEAT1 promoted autophagy in CRC cell lines. An in-depth study of its molecular mechanism revealed that NEAT1 targeted miR-34a, while miR-34a was shown to target putative binding sites in the 3'-UTR, ATG9A, and ATG4B of HMGB1, which were involved in autophagy activation (140). And inhibition of the putative targets of miR-34a involved in autophagy revealed a new pathway for NEAT1 to regulate chemoresistance. Moreover, a recent study revealed that dysregulation of LncRNA GAS5 expression could induce autophagy in CRC (33). GAS5 facilitated the formation of vesicle-like structures and autolysosome structures in cells. LncRNAs frequently function as ceRNAs for modulating...
autophagy-related miRNAs. A detailed cellular mechanism explained that GAS5 enhanced PTEN expression by acting as a ceRNA of miR-222-3p, which subsequently promoted CRC cell autophagy (33). It was reported that modulation of miR-20a was substantially lower under hypoxia that facilitated hypoxia-induced autophagy in CRC cells (141). Also, research showed that the ectopic expression of circCCDC66 could interact with miR-3140 in autophagy (101).

Given that aberrant autophagy is implicated in the pathogenesis of CRC, deliberate manipulation of autophagy may be effective in treating CRC. A precise determination of autophagy activity is essential to downstream autophagy-based therapy for CRC since autophagy dynamics vary greatly within different cellular statuses, and both an increase and a decrease in autophagy can contribute to CRC pathogenesis. Consequently, the importance of tailoring interventions with autophagy regulators in CRC of particular situations rather than applying a ‘one size fits all’ approach is vital for favorable treatment outcomes.

**THE CLINICAL SIGNIFICANCE OF NCRNAS IN CRC**

The clinical significance of ncRNAs in CRC explains their capability for diagnosis, treatment, chemotherapeutic resistance, and prognosis. To date, the diagnosis of CRC is mainly dependent on colonoscopy, which is deemed as the gold standard for the diagnosis of CRC (142). Furthermore, this approach has the disadvantage of requiring intestinal preparation and the risk of intestinal rupture, and it is not suitable for patients with anorectal stenosis, peritoneal irritation, severe cardiopulmonary function, and other conditions (143). Therefore, novel biomarkers for diagnosis and effective therapeutic targets are urgently required to improve the current situation.

**ncRNAs as Potential Biomarkers for CRC Diagnosis and Prognosis**

A competent biomarker should be sensitive, specific, repeatable, stable, and useful in clinical settings. ncRNAs are attractive candidates for biomarkers due to their expression patterns and properties (universality, conservation, tissue/cell selectivity, and stability). Besides, ncRNAs are enriched in human bodily fluids, such as plasma and saliva, facilitating their detection and making them suitable markers for cancer detection, particularly in liquid biopsies. These studies suggest that ncRNAs can serve as biomarkers for improving current detection and diagnostic methods of CRC. The abnormal expression of ncRNAs in CRC should be the prerequisite for them as biomarkers in clinical practice. Furthermore, ncRNAs as a non-invasive technology thereby being an ideal diagnostic approach have attracted much attention. Research has shown that miR-29a and miR-224 could be informative biomarkers for screening and early diagnosis of CRC via a noninvasive way (144). Survival of patients with metastatic cancer is still unfavorable, and resistance to therapy remains a major barrier to effective treatment. One intriguing approach to improving cancer treatment is leveraging cancer- and tissue-specific expression profiles to develop prognostic and diagnostic markers for the progression from primary to metastatic diseases.

Ling et al. found that patients with higher miR-224 levels appeared to have unfavorable overall survival in the five CRC cohorts (145). More interestingly, the incorporated analysis with CDH1 dramatically enhanced the predictive power of miR-224 for survival evaluation instead of appraising miR-224 alone (145). In addition to the diagnostic value of miR-224, it might also become a potential prognostic marker in CRC. Another research discovered that miR-224 mediates CRC tumorigenesis through regulating Wnt/β-catenin signaling, further proving that miR-224 was a prognostic biomarker (146). Assessment of miR-203 in serum could be an attractive and promising clinical tool for identifying patients with mCRC. Serum miR-203 was significantly correlated with the metastatic phenotype of CRC and was an independent prognostic biomarker for liver, lymph node, and peritoneal metastases of CRC, respectively (147). Moreover, serum miR-203 levels were significantly upregulated in a stage-dependent manner, and higher miR-203 expression was associated with poor survival in CRC patients, which suggested that miR-203 in serum was an independent prognostic marker.

A recent study illustrated that circ0004771 expression was exceptionally up-regulated in CRC patients, implying circ0004771 could provide a novel biomarker for the diagnosis of CRC (89). Recently, evidence is accumulating that ncRNAs can be not only clinical biomarkers for the early diagnosis and detection, as well as prognosis of cancer, but also potential therapeutic targets to enhance anti-tumor responses by regulating ncRNAs.

**ncRNAs as Promising CRC Therapeutic Targets**

Chemotherapy, radiotherapy, and excision are the main therapeutic strategies for clinical CRC (148). Although the clinical treatment has been improved, patients tend to have an unfavorable prognosis, and their 5-year survival rates remain low, which seems to be relevant to the chemotherapeutic resistance of CRC cells (149). Of note, recent studies have shown that ncRNAs can affect chemo-resistance in CRC therapy (150, 151). Therefore, identifying novel therapeutic targets for optimizing CRC therapy can be achieved through understanding the regulatory mechanisms of ncRNAs involved in chemotherapy and radiotherapy resistance.

On the one hand, it is well known that 5-Fu is a commonly used chemotherapeutic agent in curing CRC, and it obstructs DNA replication by inhibiting thymidylate synthase, hence leading to cell cycle arrest and apoptosis to induce DNA damage (152). IncRNA H19 level is found to increase in CRC, and it strongly enhances the resistance of CRC cells to 5-Fu. Moreover, molecular mechanism suggests that H19 induces chemotherapy resistance by binding to the downstream target gene SIRT1 (39). On the other hand, cancer stem cells (CSC),
as one of the subpopulations of chemo-resistant cells, play a crucial role in disease recurrence after chemotherapy. miR-133b is rich in CSCs and associated with stem cell-like characteristics, mainly elevated surface markers of CSCs and enhanced chemotherapeutic resistance (53). Furthermore, miR-133b overexpression reduces stem cell gene DOT1L-mediated H3K79me2 modification, which is consistent with down-regulation of stem cell gene transcription (53). Recovery of DOT1L eliminates the inhibitory effect of miR-133b on stem cell and CRC chemoresistance (54). miR-27a is observed to be overexpressed in the progress of anti-therapy of CRC. More importantly, miR-27a can act as a key regulatory factor engaging in metabolism reprogramming that might stimulate the mechanism concerning the chemical resistance of CRC (153).

The features of ncRNAs in CRC elucidate they act as promising treatment candidates for new therapeutic interventions. It is noticeable that circRNA PTK2 interacting with vimentin exerts a catalytic role during CRC growth and metastasis (154). In addition, vein injection of shRNA distinctively targeting circPTK2 immensely blunts CRC metastasis among the patient-derived xenograft models (154). Therefore, circPTK2 might afford an unrealized therapeutic target for the remedy of CRC metastasis. The ability to manipulate ncRNA expression and activity in vivo through anti-ncRNAs or ncRNA mimics provides an opportunity for developing innovative therapeutic approaches to CRC. miRNA dysregulation is causal in many cancer cases. miRNA mimics and molecules capable of targeting miRNAs have shown promise in preclinical development. Numerous strategies have been investigated to complement miRNAs with tumor suppressor functions by using miRNA mimics, which are synthetic oligonucleotide duplexes that mimic the function of their naturally occurring miRNA counterparts. Such miRNA mimics can be chemically modified to be more stable or capable of targeted delivery to tumors. miR–34a mimics can be encapsulated into TCP1-CD-QD nanoparticles and transferred into CRC cells, which contributes to the suppression of the proliferation and migration of CRC cells in vitro and inhibition of tumor growth in a tumor xenograft model derived from CRC cells (155). Moreover, the obtained indicates that co-delivery of miR-34a mimics and 5-FU could achieve synergistic effects for CRC treatment.

Although only a few typical ncRNAs related to chemoresistance are included in this review, more ncRNAs regulating CRC radiotherapy and chemoresistance need to be further explored. On the other hand, explaining the underlying mechanisms of ncRNAs in predicting treatment responses and managing individualized treatment choices appears to be another interesting aspect. Particularly, the combination of ncRNAs and chemotherapeutic agents to sensitize CRC seems promising and worthy of clinical trials. Future studies focusing on the regulation of ncRNAs in CRC chemo-resistance may contribute to certifying ncRNAs as encouraging therapeutic candidates. With the increasing involvement of ncRNAs revealed by the studies of chemoradiation resistance in CRC cells, as novel biomarkers, ncRNAs have great potential not only for predicting the efficiency of chemoradiation and prognosis, but for interfering with chemo-radiation resistance as targets in clinical CRC therapies.

**Other Clinical Significance of ncRNAs in CRC**

In addition to being potentially applied as diagnostic or prognostic biomarkers and therapeutic targets of CRC, the dysregulation of ncRNAs is correlated with the TNM stage, lymphatic metastasis, tumor size, and differentiation grade. For example, circ103809 participates in TNM staging of CRC and can be used as a biomarker (94). The expression of IncRNA DANCER is highly upregulated in CRC, which is associated with the TNM stage (156). Statistical analysis has demonstrated that IncRNA RPPH1 is positively associated with advanced TNM (157). Furthermore, in situ hybridization showed that high expression of RPPH1 in advanced TNM stage was associated with poor metastasis and overall survival (157). Overexpression of circCAMSAP1 is tightly linked with stage and clinical stage (158). Zhang et al. have discovered that IncRNA CASC11 expression is positively associated with tumor size, lymph node metastasis, and TNM stage in CRC (159). These ncRNAs mentioned above can provide a basis for the diagnosis and grading of clinical diseases and clues for predicting the prognostic outcomes.

**CONCLUSION AND PROSPECT**

CRC-related ncRNAs are increasingly becoming one of the most scorching topics in RNA biology and oncology. To date, lncRNAs, miRNAs, and circRNAs are the most commonly investigated ncRNAs that are involved in CRC progression. Of note, the functions and mechanisms of other types of ncRNAs are still unclear but are currently emerging. For instance, it has been revealed that piRNA-54265 is extensively upregulated in CRC and the elevated expression of piRNA-54265 in tumor or serum is significantly correlated with an unfavorable prognosis. Functional assays have revealed that piRNA-54265 targets PIWIL2 protein and this is essential for the formation of PIWIL2/STAT3/ phosphorylated-SRC complex, which facilitates STAT3 signaling and enhances proliferation, metastasis as well as chemo-resistance of CRC cells (160). Several recent studies have independently unveiled that snoRNAs are involved in various cancers progression. SNORD126 is observed to be upregulated in CRC clinical samples, and it can promote tumor growth by modulating the PI3K/AKT signaling pathway rather than functioning as a miRNA (161).

The tRNA-derived fragments (tRFs) are generated through endo-nucleolytic cleavage of corresponding tRNAs and have been shown to be potential biomarkers for tumor diagnosis and treatment in several studies (162). For example, tRF levels in breast cancer cells significantly increased under hypoxia, which is consistent with their potential roles in stress response. Goodarzi et al. found that endogenous tRFs destabilize oncogenic transcripts by binding directly to YBX1 (163). Overexpression of YBX1 is associated with tumorigenic
phenotypes and has been shown to facilitate cancer metastasis (164). Furthermore, there is a high correlation between increased expression of multiple tRF-YBX1 targets (EIF4G1, EIF4EBP1 and EIF3B) and reduced recurrence-free survival. Transcripts of these oncogenes function in various aspects of cellular function, including translation and cellular signaling, and are repressed by tRFs in breast cancer cells (163). Recently, studies on the impact of CRC-related tRFs or key tRFs on CRC progression and related mechanisms are emerging. After hypoxic treatment, a total of 14 tRFs were differentially expressed in hypoxia-induced CRC RKO cells by performing tRF sequencing and real-time PCR assays. Among them, tRF-20-M0NKS93 might be a promising target for exploration, as its expression was significantly lower under hypoxic conditions than control conditions, and tRF-20-M0NKS93 inhibited CRC cell invasion and migration by targeting the EMT-related molecule Claudin-1 (165). Another study showed that tRF/miR-1280, a 17 bp fragment derived from tRNA\textsuperscript{Leu} and pre-miRNA, was low expression in CRC study showed that tRF/miR-1280, a 17 bp fragment derived from tRNA\textsuperscript{Leu} and pre-miRNA, was low expression in CRC specimens. Mechanistic investigations indicated that the Notch ligand JAG2 was a direct target of tRF/miR-1280 binding and that tRF/miR-1280 inhibited colorectal cancer growth and metastasis by suppressing the Notch signaling pathway that supported the CSC phenotype (166). As for the other ncRNAs, such as eRNAs and paRNAs, no study has reported any strong connections between the ectopic expression of these ncRNAs and human cancers.

In recent years, a limited number of proteins or peptides encoded by ncRNAs have been demonstrated to exhibit significant biological and pathological functions in the tumorigenesis and progression of CRC. For example, it has been reported that IncRNA HOXB-AS3 encodes a conserved 53-aa peptide that inhibits CRC growth by regulating the reprogramming of tumor metabolism and alternative splicing of pyruvate kinase (167). Additionally, function experiments have revealed that circMAPK14-175aa (a 175 amino acid peptide) encoded by circRNA MAPK14 can suppress the CRC malignant phenotype, thus affecting CRC progression and metastasis (168). Currently, some IncRNAs and circRNAs have been shown to encode proteins or peptides, and studies on the coding functions of miRNAs are emerging. A protein and a peptide (miPES-200a and miPES-200b) encoded by pri-miRNA (miR-200a and miR-200b) suppress the migration of prostate cancer cells by inhibiting the EMT process (8). These findings broaden the understanding of ncRNA and provide further insight into the function of ncRNAs.

The intestinal microbiota, composed of a considerable population of microorganisms, is maintained by dynamic host-microbiota interactions (169). Numerous studies have shown a link between intestinal dysbiosis and CRC (170). The roles of intestinal microorganisms in initiating and facilitating the CRC process are being increasingly understood. However, few studies focus on ncRNAs in the modulation of dynamic host-microbiota interactions, and the molecular regulators of ncRNAs in intestinal microbiota are still not fully understood. The existence of thousands of ncRNAs involved in the intracellular network regulation obtains essential implications for our understanding of CRC, which in turn forces us to develop our unique view of the disorder, from its causative origins to available treatment options and additional treatment strategies.

The contribution of ncRNAs in the genesis and progression of human illnesses is gaining popularity, but more research is needed to identify the entire extent of this contribution and the processes by which ncRNAs exert their pathological effects. Consequently, what comes to the first is a more pronounced understanding of ncRNAs function and mechanisms, both in CRC physiological and pathological conditions. In this review, we have summarized the latest research on ncRNAs that operate as promoters or tumor suppressors participating in CRC proliferation, apoptosis, invasion, metastasis, angiogenesis, autophagy, and chemoresistance. Recent research has improved our conception of ncRNAs: not only do they perform fundamental operations in the normal physiological management processes, but also take part in abnormal pathologic regulatory processes. Although the research on ncRNAs has made great progress in recent years, the molecular mechanisms of administering aspects in CRC are still not clear, and further detailed mechanism research is urgently needed. Therefore, more pioneering studies are required for further exploration of the diagnostic and therapeutic opportunities that ncRNAs offer.

**REFERENCES**

1. Yamashita R, Long J, Longacre T, Peng L, Berry G, Martin B, et al. Deep Learning Model for the Prediction of Microsatellite Instability in Colorectal Cancer: A Diagnostic Study. *Lancet Oncol* (2021) 22(1):132–41. doi: 10.1016/S1470-2045(20)30535-0

2. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal Cancer. *Nature* (2012) 487(7407):330–7. doi: 10.1038/\textit{nature11252

3. Zhou XY, Luo B, Jiang ZK, Xie YK, Wu FC, Huang JQ, et al. Non-Coding RNAs and Colorectal Cancer Liver Metastasis. *Mol Cell Biochem* (2020) 475 (1-2):151–9. doi: 10.1007/s11010-020-03867-8

4. Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R, et al. The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. *Int J Mol Sci* (2018) 19(12). doi: 10.3390/ijmss19123711

**AUTHOR CONTRIBUTIONS**

FZ collected the related paper. ZJ wrote the draft and revised it. JA and ZL collected the tables and designed them. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We thank Yang Yang for making grammatical corrections to the manuscript.
6. Ogunwobi OI, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. *Int J Mol Sci* (2020) 21(15), doi: 10.3390/ijms21155311

7. Anastasiadou E, Jacob LS, Slack FJ. Non-Coding RNA Networks in Cancer. *Nat Rev Cancer* (2018) 18(5):15–18, doi: 10.1038/nrc.2017.99

8. Wang J, Zhu S, Meng N, He Y, Lu R, Yan GR. ncRNA-Encoded Peptides or Proteins and Cancer. *Mol Ther* (2019) 27(10):1718–25, doi: 10.1016/j.ymthe.2019.09.001

9. Lei B, Tian Z, Fan W, Ni B. Circular RNA: A Novel Biomarker and Therapeutic Target for Human Cancers. *Int J Med Sci* (2019) 16(2):292–301, doi: 10.7150/ijms.28047

10. Statello L, Guo C-J, Chen L-L, Huarte M. Gene Regulation by Long Non-Coding RNAs and Its Biological Functions. *Nat Rev Mol Cell Biol* (2021) 22(2):96–118, doi: 10.1038/s41573-020-00315-9

11. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA Therapeutics and Challenges and Potential Solutions. *Int J Mol Sci* (2021) 22(7):2511, doi: 10.3390/ijms22072511

12. Tai Y, Rinn J, Pandolfini B. Genome Regulation by Long Non-Coding RNAs and Its Biological Functions. *Nature* (2021) 591(7850):344–52, doi: 10.1038/d41580-020-00634-0

13. Rinn JL, Chang HY. Identification of miRNAs, Targets and Functions. *Annu Rev Biochem* (2012) 81:145–66, doi: 10.1146/annurev-biochem-051410-092902

14. Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the Development of miRNA Bioinformatics Tools. *Brief Bioinform* (2019) 20(5):836–52, doi: 10.1093/bib/bby054

15. Liu B, Li J, Cairns MJ. Identifying miRNAs, Targets and Functions. *Brief Bioinform* (2014) 15(1):1–19, doi: 10.1093/bib/bbs075

16. Peng WX, Koirala P, Mo YY. LncRNA-Mediated Regulation of Cell Signaling in Cancer. *Oncogene* (2017) 36(41):5661–7, doi: 10.1038/onc.2017.184

17. Rinn JL, Chang HY. Genome Regulation by Long Noncoding RNAs. *Annu Rev Biochem* (2012) 81:145–66, doi: 10.1146/annurev-biochem-051410-092902

18. Deng X, Li S, Kong F, Ruan H, Xu X, Zhang X, et al. Long Noncoding RNA PHIL Regulates P53 Protein Stability Through GRWD1/RPL11/MDM2 Axis in Colorectal Cancer. *Theranostics* (2020) 10(1):265–80, doi: 10.7150/thno.36045

19. Li C, Wang P, Du J, Chen J, Liu W, et al. LncRNA GAS5 Functions as a ceRNA to Promote Colorectal Cancer Growth and Migration Through Integrin-Mediated Focal Adhesion Signaling. *Mol Ther J Am Soc Gene Ther* (2021) 30: doi: 10.1038/j.ymthe.2021.08.011

20. Duan W, Kong X, Li J, Li P, Zhao Y, Liu T, et al. LncRNA AC010789.1 Promotes Colorectal Cancer Progression by Targeting MicroRNA-432-3p/ ZEB1 Axis and the Wnt/beta-Catenin Signaling Pathway. *Front Cell Dev Biol* (2020) 8:565335, doi: 10.3389/fcell.2020.565335

21. Tang Y, Yang R, Tang M, Huang P, Liao Z, Zhou J, et al. LncRNA DNAJC3-AS1 Regulates Fatty Acid Synthase via the EGFR Pathway to Promote the Progression of Colorectal Cancer. *Front Oncol* (2020) 10:604534, doi: 10.3389/fonc.2020.604534

22. Jia et al. Non-Coding RNAs in Colorectal Cancer. *Frontiers in Oncology* (2022) 12: doi: 10.3389/fonc.2021.783079
Hwang W-L, Jiang J-K, Yang S-H, Huang T-S, Lan H-Y, Teng H-W, et al. Long non-Coding RNA HOTTIP Is Highly Expressed in Colorectal Cancer and Enhances Cell Proliferation and Invasion. *Mol Ther Nucleic Acids* (2020) 19:612-8. doi: 10.1016/j.omtn.2019.12.008

Liu T, Yu T, Hu H, He K. Knockdown of the Long non-Coding RNA HOTTIP Inhibits Colorectal Cancer Cell Proliferation and Migration and Induces Apoptosis by Targeting SGK1. *Biomed Pharmacother* (2018) 98:286–96. doi: 10.1016/j.biopha.2017.12.064

Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnic BA, Rozyczki EB, et al. Long non-Coding RNA RAMS11 Promotes Metastatic Colorectal Cancer Progression. *Nat Commun* (2020) 11(1):2156. doi: 10.1038/s41467-020-15547-7

Islam Khan MZ, Law HKW. RAMS11 Promotes CRC Through mTOR-Dependent Inhibition of Autophagy, Suppression of Apoptosis, and Promotion of Epithelial-Mesenchymal Transition. *Cancer Cell Int* (2021) 21(1):321. doi: 10.1186/s12935-021-02023-6

Michael MZ, OC SM, van Holst Pellekaan NG, Young GP, James RJ. NOTCH2-Mediated EMT Modulates IL-4 Secretion in Colorectal Cancer to Promote the Symmetric Division of Snail-Dominant Cancer Cell Stemness and Chemoresistance. *Clin Sci (Lond Engl 1979)* (2020) 134(9):419-34. doi: 10.1042/CS20191087

Sun L, Fang Y, Wang X, Han Y, Du F, Li C, et al. miR-30a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIP and CD44. *Theranostics* (2019) 9(6):52-67. doi: 10.7150/thno.36605

Xu W, Chen B, Ke D, Chen X. MicroRNA-138-5p Targets the NFIB-Snail1 Axis to Inhibit Colorectal Cancer Cell Migration and Chemoresistance. *Cancer Cell Int* (2020) 20:475. doi: 10.1186/s12935-020-01573-5

Bleau A-M, Redrado M, Nistal-Villan E, Villalta M, Exposito F, Redin E, et al. miR-146a Targets C-Met and Abolishes Colorectal Liver Metastasis. *Cancer Lett* (2018) 414:257–67. doi: 10.1016/j.canlet.2017.11.008

Hwang W-L, Jiang J-K, Yang S-H, Huang T-S, Lan H-Y, Teng H-W, et al. MicroRNA-146a Directs the Symmetric Division of Snail-Dominant Colorectal Cancer Stem Cells. *Nat Cell Biol* (2014) 16(3):268–80. doi: 10.1038/ncl29810

Lin X, Wang S, Sun M, Zhang C, Wei C, Yang C, et al. miR-195-5p/NOTCH2-Mediated EMT Modulates IL-4 Secretion in Colorectal Cancer to Affect M2-Like TAM Polarization. *J Hematol Oncol* (2019) 12(1):20. doi: 10.1186/s13045-019-0708-7

Jin Y, Wang M, Hu H, Huang Q, Chen Y, Wang G. Overcoming Stemness and Chemoresistance in Colorectal Cancer Through miR-195-5p-Mediated Inhibition of Notch Signaling. *Int J Biol Macromol* (2018) 117:445–53. doi: 10.1016/j.ijbiomac.2018.05.151

Xin H, Wang C, Chi Y, Liu Z. MicroRNA-196b-5p Promotes Malignant Progression of Colorectal Cancer by Targeting NG5s. *Cancer Cell Int* (2020) 20:119. doi: 10.1186/s12935-020-02030-0

Zhou Z, Wu L, Liu Z, Zhang X, Han S, Zhao N, et al. MicroRNA-214-3p Targets the PLAGL2-MYH9 Axis to Suppress Tumor Proliferation and Metastasis in Human Colorectal Cancer. *Aging (Albany NY)* (2020) 12(10):6633–57. doi: 10.18632/aging.103233

Li J, Peng W, Yang P, Chen R, Gu Q, Qian W, et al. MicroRNA-1224-5p Inhibits Metastasis and Epithelial-Mesenchymal Transition in Colorectal Cancer by Targeting SP1-Mediated NFKB Signaling Pathways. *Front Oncol* (2020) 10:294. doi: 10.3389/fonc.2020.00294

Li SS, Zhu HJ, Li JY, Tian LM, Lv DM. MiRNA-875-3p Alleviates the Progression of Colorectal Cancer via Negatively Regulating PLK1. *Eur Rev Med Pharmacol Sci* (2020) 24(3):1126–33. doi: 10.26355/eurr202002_20163

Shahmohamadnejad S, Nouri Ghonbalani Z, Tahbrazilahi B, Panahi G, Meskani R, Emami Razavi A, et al. Aberrant Methyltion of miR-124 Upregulates DNMT3B in Colorectal Cancer to Accelerate Invasion and Migration. *Arch Physio Biochem* (2020) 128:1–7. doi: 10.1080/13813455.2020.1779311

Roshani Asl E, Rasmji Y, Baradaran B. MicroRNA-124-3p Suppresses PD-L1 Expression and Inhibits Tumorigenesis of Colorectal Cancer Cells via Modulating STAT3 Signaling. *J Cell Physiol* (2021) 236(10):7071–87. doi: 10.1002/jcp.30378

Rupaimoole R, Slack FJ. MicroRNA Therapeutics: Towards a New Era for the Management of Cancer and Other Diseases. *Nat Rev Drug Discov* (2017) 16(3):203–22. doi: 10.1038/nrd.2016.246

Deng S, Wang H, Fan H, Zhang L, Hu J, Tang Q, et al. Over-Expressed miRNA-208b Ameliorates Ulcerative Collitis-Related Colorectal Cancer in Mice Through Orchestrating Epithelial-Mesenchymal Transition and Inflammatory Responses by Channel of AKT2. *Int Immunopharmacol* (2018) 61:346–54. doi: 10.1016/j.intimm.2018.06.024

Normann N, Teijpar S, Morgillio F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS Status and EGFR-Targeted Therapies in Metastatic CRC. *Nat Rev Clin Oncol* (2009) 6(9):519–27. doi: 10.1038/nrclinonc.2009.111

Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. *N Engl J Med* (2008) 358(11):1160–74. doi: 10.1056/NEJMra0707704

Hotta M, Seto M, Iijichi H, Miyabayashi K, Kudo Y, Mohri D, et al. Decreased Expression of the RAS-GTPase Activating Protein RASAL1 Is Associated With Colorectal Tumor Progression. *Gastroenterology* (2009) 136(1):206–16. doi: 10.1053/j.gastro.2008.09.063

Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium Nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kb, and Up-Regulating Expression of MicroRNA-21. *Gastroenterology* (2017) 152(4):851–66. doi: 10.1056/NEJMoa1700415

Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a Induce Cyclin D1 Expression Through ErbB1 Transactivation in HC11 Mammary Epithelial Cells. *EMBO Rep* (2003) 4(2):166–71. doi: 10.1038/sj.embor.embor07575

Du F, Cao T, Xie H, Li T, Sun L, Liu H, et al. KRAS Mutation-Responsive miR-139-5p Inhibits Colorectal Cancer Progression and is Repressed by Wnt Signaling. *Theranostics* (2020) 10(16):7335–50. doi: 10.7150/thno.45971

Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, et al. Exosome-Transmitted miR-128-3p Increases Chemosensitivity of Oxaliplatin-Resistant Colorectal Cancer. *Mol Cancer* (2019) 18(1):43. doi: 10.1186/s12943-019-0988-7

Xu D, Wu Y, Wang X, Hu Q, Qin W, Li Y, et al. Identification of Functional circRNA/miRNA/mRNA Regulatory Network for Exploring Prospective Therapy Strategy of Colorectal Cancer. *J Cell Biochem* (2020) 121:4785–97. doi: 10.1002/jcb.29703
81. Deng Q, Wang CJ, Hao R, Yang QY. Circ_001982 Accelerates the Progression of Colorectal Cancer via Sponging microRNA-144. *Eur Rev Med Pharmacol Sci* (2020) 24(4):1755–62. doi: 10.26355/eurev_202002_02352
82. Chen J, Yang J, Fei X, Wang X, Wang K. CircRNA ciRS-7: A Novel Oncogene in Multiple Cancers. *Int J Biol Sci* (2021) 17(1):379–89. doi: 10.7150/ijbis.54292
83. Weng W, Wei Q, Toden S, Yoshida K, Nagasaki T, Fujitawa T, et al. Circular RNA ciRS-7: A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer. *Clin Cancer Res* (2017) 23(14):3918–28. doi: 10.1158/1078-0432.CCR-16-2541
84. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF Signaling Pathway in Cancer Therapy. *Expert Opin Ther Targets* (2012) 16(1):103–19. doi: 10.1517/14782221.2011.645805
85. Qu S, Yang X, Li X, Wang J, Gao Y, Cai Y, Tang Y, et al. Circular RNA: A New Star of Noncoding RNAs. Cancer Lett (2015) 352(6):141–8. doi: 10.1016/j.canlet.2015.06.003
86. Chen L-Y, Wang L, Ren Y-X, Pang Z, Liu Y, Sun X-D, et al. The Circular RNAs Hsa_circRNA_102209 Promotes the Growth and Metastasis of Colorectal Cancer by Sponging miR-761-Mediated Ras and PI3K/AKT Pathway. *Aging* (2018) 10:1560–70. doi: 10.1002/1878-0261.12629
87. Deng Z, Li X, Wang H, Geng Y, Cai Y, Tang Y, et al. Dysregulation of Exosomal circRNA Promotes Metastasis of Colorectal Cancer via Targeting GEF-H1/RhoA Axis. *Theranostics* (2020) 10(18):8211–26. doi: 10.7150/thno.44119
88. Xu H, Liu Y, Cheng P, Wang C, Liu Y, Zhou W, et al. CircRNA_0000392 and Metastasis of Colorectal Cancer Through miR-122-PKM2 Axis. *Biochem Biophys Res Commun* (2020) 515(2):346–52. doi: 10.1016/j.bbrc.2018.08.152
89. Li R, Wu B, Xia J, Ye L, Yang X. Circular RNA Hsa_circRNA_102958 Regulated the Cell Proliferation and Migration in Colorectal Cancer. *Cancer Med* (2020) 9(18):6710–25. doi: 10.1002/cam4.3560
90. Deng Q, Wang CJ, Hao R, Yang QY. Circ_0001982 Accelerates the Progression of Colorectal Cancer. *Mol Cancer* (2020) 19:117. doi: 10.1186/s12885-019-6028-z
91. Wang X, Zhang H, Yang Y, Wang X, Deng T, Liu R, et al. Hsa_circRNA_103809 and Metastasis of Colorectal Cancer Through Regulating miR-615-5p/LARP1/mTOR Pathway. *Mol Cancer* (2020) 19(5):356. doi: 10.1038/s41419-020-2514-0
92. Lu H, Yao B, Wen J, Xia J, Cai Y. FNDC3B Exosomal circRNA Promotes Metastasis of Colorectal Cancer via miR-142-3p/miR-306-3p–TGF-Beta1 Axis. *Mol. Cancer* (2020) 19(1):117. doi: 10.1186/s12943-019-01235-0
93. Zeng W, Liu Y, Li WT, Li ZH, Zhe FJ. CircFNDC3B Sequestrates miR-937–5p to Derepress TIMP3 and Inhibit Colorectal Cancer Progression. *J Exp Clin Cancer Res* (2020) 14(11):2906–84. doi: 10.1016/j.scr.2020.06.089
94. Chen C, Huang Z, Mo X, Song Y, Li X, Li X, et al. The Circular RNA 001971/miR-29c–3p Axis Modulates Colorectal Cancer Growth, Metastasis, and Angiogenesis Through VEGFA. *J Exp Clin Cancer Res* (2020) 39(1):91. doi: 10.1186/s13046-020-01279-6
95. Zhang X, Zhao Y, Kong P, Han M, Li B. Expression of Circzfn609 is Down-Regulated in Colorectal Cancer Tissue and Promotes Apoptosis in Colorectal Cancer Cells by Upregulating P53. *Med Sci Monit* (2019) 25:5977–85. doi: 10.12659/MSM.919529
96. Yuan Y, Liu W, Zhang Y, Zhang Y, Sun S. CircRNA_0026344 as a Prognostic Biomarker Suppresses Colorectal Cancer Progression via microRNA-21 and microRNA-31. *Biochim Biophys Acta* (2020) 503(2):870–5. doi: 10.1016/j.bbrc.2018.06.089
97. Du J, Xu J, Chen J, Liu W, Wang P, Ye K. Circetna1 Promotes Colorectal Cancer Cell Migration and Invasion by Modulating miR-338–3p/TPR03 Axis. *Cancer Cell Int* (2020) 20:430. doi: 10.1186/s12952-020-01519-x
98. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
99. Li G, Zhou L-N, Yang H, He X, Duan Y, Wu F. Ninjinurin 2 Overexpression Promotes Human Colorectal Cancer Cell Growth and Aging. *Aging* (2019) 11(19):8526–41. doi: 10.18632/aging.102336
100. Pistritto G, Trisciuoglio D, Ceci C, Garufi D, D’Orazi G, Apiccis as Anticancer Mechanism: Function and Dysfunction of its Modulators and Targeted Therapeutic Strategies. *Aging* (2016) 8(4):603–19. doi: 10.18632/ageing.100934
101. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-Catenin Pathway in Cancer: Update on Effectors and Inhibitors. *Cancer Treat Rev* (2018) 62:50–60. doi: 10.1016/j.ctrv.2017.11.002
102. Bugarin JM, Fierendos N, Maurice MM. Mutations and Mechanisms of WNT Pathway Suppressor in Colon Tumors. *Nat Rev Cancer* (2021) 21(5):1–21. doi: 10.1038/s41568-020-00307-z
103. Xu J, Han Z, Sun Z, Wang Y, Zheng M, Song C. LncRNA SLCO4A1-AS1 Facilitates Growth and Metastasis of Colorectal Cancer Through Beta-Catenin-Dependent Wnt Pathway. *J Exp Clin Cancer Res* (2020) 39(1):1722. doi: 10.1186/s13046-018-0896-y
104. Wang J, Zhang Y, Song H, Yin H, Jiang T, Xu Y, et al. The Circular RNA circSPARC Enhances the Migration and Proliferation of Colorectal Cancer by Regulating the JAK/STAT Pathway. *Mol. Cancer* (2021) 20(1):81. doi: 10.1186/s12943-021-01375-x
117. Taherdangkoo K, Kazemi Nezhad SR, Hajjari MR, Tahmasebi Birgani M. miR-485-3p Suppresses Colorectal Cancer via Targeting TPX2. Bratil Sek Lek (2019) 21(4):38–42. doi: 10.1016/j.let.2019.07.008

118. Martin TD, Patel RS, Cook DR, Choi MY, Patil A, Liang AC, et al. The Adaptive Immune System is a Major Driver of Selection for Tumor Suppressor Gene Inactivation. Science (2021) 373(6561):1327–35. doi: 10.1126/science.abf5784

119. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its Microenvironment: A Synergistic Interplay. Semin Cancer Biol (2013) 23 (6 Pt B):522–32. doi: 10.1016/j.semcancer.2013.08.007

120. Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (2017) 9(12). doi: 10.3390/cancers9120171

121. Klein CA. Cancer Progression and the Invisible Phase of Metastatic Colonization. Nat Rev Cancer (2020) 20(11):681–94. doi: 10.1038/s41568-020-00300-6

122. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular Principles of Metastasis: A Hallmark of Cancer Revisited. Signal Transduct Target Ther (2020) 5(1):28. doi: 10.1038/s41392-020-0134-x

123. Ji Q, Cai G, Liu X, Zhang Y, Wang Y, Zhou L, et al. MALAT1 Regulates the Transcriptional and Translational Levels of Proto-Oncogene RUNX2 in Colorectal Cancer Metastasis. Cell Death Dis (2019) 10(6):378. doi: 10.1038/s41419-019-1598-x

124. Zhou W, Ye X, Xu J, Cao MG, Fang ZY, Li LY, et al. The IncRNA H19 Mediates Breast Cancer Cell Plasticity During EMT and MTT Plasticity by Differentially Sponging miR-200C and Let-7b. Sci Signal (2017) 10(483). doi: 10.1126/scisignal.aas9557

125. Herrera-Solorio AM, Peralta-Arrieta I, Armas Lopez L, Hernandez-Cigala N, Mendoza Millia C, Ortiz Quintero B, et al. LncRNA SOX2-OT Regulates Its Microenvironment: A Synergistic Interplay. Gut (2020) 69(7):1631–44. doi: 10.1136/gutjnl-2015-310691

126. Zhu YX, Xu AD, Li J, Fu FH, Wang GH, Yang YL, et al. Fecal miR-29a and miR-224 as the Noninvasive Biomarkers for Colorectal Cancer. Cancer Biomark (2016) 16(2):259–64. doi: 10.3233/Cbm-150563

127. Ling H, Pickard K, Ivan C, Isella C, Ikouo M, Mitter R, et al. The Clinical and Biological Significance of MIR-224 Expression in Colorectal Cancer Metastasis. Gut (2016) 65(9):877–89. doi: 10.1136/gutjnl-2015-309372

128. Li T, Liu Q, Wang S, Cai J, Xiao Z, Deng D, et al. MicroRNA-224 Sustains Wnt/beta-Catenin Signaling and Promotes Aggressive Phenotype of Colorectal Cancer. J Exp Clin Cancer Res (2016) 35:21. doi: 10.1186/s13046-016-0287-1

129. Hur K, Tajoyma Y, Okagawa Y, Ide S, Imaoka H, Boland CR, et al. Circulating microRNA-203 Predicts Prognosis and Metastasis in Human Colorectal Cancer. Gut (2017) 66(4):654–65. doi: 10.1136/gutjnl-2016-308737

130. Pidikova P, Reis R, Herrichova I. miRNA Clusters With Down-Regulated Expression in Human Colorectal Cancer and Their Regulation. Int J Mol Sci (2021) 22(13). doi: 10.3390/ijms21134633

131. Micallef I, Baron B. The Mechanistic Roles of miRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer. Noncoding RNA (2021) 7 (2). doi: 10.3979/nrnc720024

132. Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 Is Associated With Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance Through EZH2. Mol Cancer Ther (2017) 16(4):739–51. doi: 10.1158/1535-7186.Mct-16-0591

133. Fanale D, Castiglia M, Bazan V, Russo A. Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. Adv Exp Med Biol (2016) 937:287–298. doi: 10.1007/978-3-319-42059-2_11

134. Lei W, Liu X, Lv L, Zhang Y, Yang G, Yang M. The Emerging Role of Noncoding RNAs in Colorectal Cancer Chemoresistance. Cell Oncol (Dordr) (2019) 42(6):757–68. doi: 10.1007/s13402-019-00466-8

135. Barisciano G, Colangelo T, Rosato V, Muccillo L, Taddei ML, Ippolito L, et al. miR-27a is a Master Regulator of Metabolic Reprogramming and Chemoresistance in Colorectal Cancer. Br J Cancer (2020) 122(9):1354–66. doi: 10.1038/s41416-020-0773-2

136. Yang H, Li X, Meng Q, Sun H, Wu S, Hu W, et al. CircPTK2 (Hsa_Circ_0005273) as a Novel Therapeutic Target for Metastatic Colorectal Cancer. Mol Cancer (2020) 19(13). doi: 10.1186/s12935-020-1139-3

137. Xu J, Zhang G, Luo X, Wang D, Zhou W, Zhang Y, et al. Co-Delivery of 5-Fluorouracil and miRNA-34a Mimics by Host-Guest Self-Assembly Nanocarriers for Efficacious Targeted Therapy in Colorectal Cancer Patient-Derived Tumor Xenografts. Theranostics (2021) 11(5):2475–89. doi: 10.7150/thno.52076

138. Liu Y, Zhang M, Liang L, Li J, Chen YX. Over-Expression of IncRNA DANCR is Associated With Advanced Tumor Progression and Poor Prognosis in Patients With Colorectal Cancer. Int J Clin Exp Pathol (2015) 8(11):4980–4.

139. Liang ZX, Liu HS, Wang FW, Xiong L, Zhou C, Hu T, et al. LncRNA RPPH1 Promotes Colorectal Cancer Metastasis by Interacting With TUBB3 and by Promoting Exosomes-Mediated Macrophage M2 Polarization. Cell Death Dis (2019) 10(11):829. doi: 10.1038/s41419-019-2077-0
158. Zhou C, Liu HS, Wang FW, Hu T, Liang ZX, Lan N, et al. Circamsap1 Promotes Tumor Growth in Colorectal Cancer via the miR-328-5p/E2F1 Axis. *Mol Ther* (2020) 28(3):914–28. doi: 10.1016/j.mther.2019.12.008

159. Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, et al. Long non-Coding RNA CASC11 Interacts With hnRNP-K and Activates the WNT/beta-Catenin Pathway to Promote Growth and Metastasis in Colorectal Cancer. *Cancer Lett* (2016) 376(1):62–73. doi: 10.1016/j.canlet.2016.03.022

160. Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R, et al. PIWI-Interacting RNA-54265 is Oncogenic and a Potential Therapeutic Target in Colorectal Adenocarcinoma. *Theranostics* (2018) 8(19):5213–30. doi: 10.7150/thno.28001

161. Fang X, Yang D, Luo H, Wu S, Dong W, Xiao J, et al. SNORD126 Promotes HCC and CRC Cell Growth by Activating the PI3K-AKT Pathway Through FGFR2. *J Med Cell Biol* (2017) 9(3):243–55. doi: 10.1093/jmcb/mjw048

162. Thompson DM, Parker R. Stressing Out Over tRNA Cleavage. *Cell* (2009) 138(2):215–9. doi: 10.1016/j.cell.2009.02.053

163. Goodarzi H, Liu X, Nguyen HCR, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. *Cell* (2015) 161(4):790–802. doi: 10.1016/j.cell.2015.02.053

164. Jürchott K, Kuban R-J, Krech T, Blüthgen N, Stein U, Walther W, et al. Identification of Y-Box Binding Protein 1 as a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells. *PloS Genet* (2010) 6(12):e1001231. doi: 10.1371/journal.pgen.1001231

165. Luan N, Chen Y, Li Q, Mu Y, Zhou Q, Ye X, et al. TRF-20-M0NK5Y93 Suppresses the Metastasis of Colon Cancer Cells by Impairing the Epithelial-to-Mesenchymal Transition Through Targeting Claudin-1. *Am J Trans Res* (2021) 13(1):124–42.

166. Huang B, Yang H, Cheng X, Wang D, Fu S, Shen W, et al. tRF/miR-1280 Suppresses Stem Cell-Like Cells and Metastasis in Colorectal Cancer. *Cancer Res* (2017) 77(12):3194–206. doi: 10.1158/0008-5472.CAN-16-3146

167. Huang J-Z, Chen M, Chen D, Gao X-C, Zhu S, Huang H, et al. A Peptide Encoded by a Putative IncRNA HOXB-AS3 Suppresses Colon Cancer Growth. *Mol Cell* (2017) 68(1):171–84. doi: 10.1016/j.molcel.2017.09.015

168. Wang L, Zhou J, Zhang C, Chen R, Sun Q, Yang P, et al. A Novel Tumour Suppressor Protein Encoded by Circmapk14 Inhibits Progression and Metastasis of Colorectal Cancer by Competitively Binding to MKK6. *Clin Trans Med* (2021) 11(10):e613. doi: 10.1002/ctm2.613

169. Dong J, Tai JW, Lu L-F. miRNA-Microbiota Interaction in Gut Homeostasis and Colorectal Cancer. *Trends Cancer* (2019) 5(11):666–9. doi: 10.1016/j.trecan.2019.08.003

170. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell* (2018) 33(6):3194–206. doi: 10.1016/j.ccel.2018.03.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jia, An, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.